P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors

Extracellular ATP (eATP) is a signaling molecule that variably affects all cells of the immune system either directly or after hydrolysis to adenosine. Although eATP is virtually absent in the interstitium of normal tissues, it can be present in the hundreds of micromolar range in tumors, a concentr...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 80; no. 18; pp. 3906 - 3919
Main Authors Romagnani, Andrea, Rottoli, Elsa, Mazza, Emilia Maria Cristina, Rezzonico-Jost, Tanja, De Ponte Conti, Benedetta, Proietti, Michele, Perotti, Michela, Civanelli, Elisa, Perruzza, Lisa, Catapano, Alberico L., Baragetti, Andrea, Tenedini, Elena, Tagliafico, Enrico, Falzoni, Simonetta, Di Virgilio, Francesco, Norata, Giuseppe Danilo, Bicciato, Silvio, Grassi, Fabio
Format Journal Article
LanguageEnglish
Published United States 15.09.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Extracellular ATP (eATP) is a signaling molecule that variably affects all cells of the immune system either directly or after hydrolysis to adenosine. Although eATP is virtually absent in the interstitium of normal tissues, it can be present in the hundreds of micromolar range in tumors, a concentration compatible with activation of the ATP-gated ionotropic P2X7 receptor. Here, we show that P2X7 activity in tumor-infiltrating lymphocytes (TIL) induces cellular senescence and limits tumor suppression. P2X7 stimulation affected cell cycling of effector T cells and resulted in generation of mitochondrial reactive oxygen species and p38 MAPK-dependent upregulation of cyclin-dependent kinase inhibitor 1A (Cdkn1a, encoding for p21Waf1/Cip1). Lack of P2X7 promoted a transcriptional signature that correlated with enhanced cytotoxic T-cell response in human solid tumors. In mice, transfer of tumor-specific T cells with deletion of P2rx7 significantly reduced tumor growth and extended survival. Collectively, these findings uncover a purinergic checkpoint that can be targeted to improve the efficacy of cancer immunotherapy strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland (A.R.); Laboratory of Translational Immunology, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy (E.M.C.M.); CCI-Center for Chronic Immunodeficiency, Universitätsklinikum Freiburg, 79106 Freiburg, Germany (M.P.).
ISSN:0008-5472
1538-7445
1538-7445
DOI:10.1158/0008-5472.CAN-19-3807